Synokem Pharmaceuticals

What Synokem Pharmaceuticals does

Synokem Pharmaceuticals Ltd. is an Indian pharmaceutical company founded in 1983 and headquartered in Delhi, operating an integrated CDMO-plus-product platform across four verticals: contract manufacturing/CDMO services for pharma and biotech customers; a Branded Rx/Ethical Division for prescription medicines in India; an Institutional Business supplying government departments, public sector hospitals, state procurement corporations, Indian Railways, and the Jan Aushadhi program; and an International Business exporting WHO-GMP-certified formulations to more than 30-35 countries across Africa, LATAM, the Middle East, CIS, SAARC, and Southeast Asia.

Its core manufacturing is delivered through three wholly-owned subsidiaries with WHO-GMP and cGMP certification: Synokem Lifesciences (Plant 3, incorporated 2022; tablets, capsules, liquids and home of the DSIR-certified R&D center including the F&D team and Analytical Development Laboratory), Nitin Lifesciences (acquired 2023; CDMO focused on Small Volume Parenteral products — glass vials, dry powder injections, glass ampoules, lyophilized injections, eye/ear drops — with 30+ years of aseptic expertise and three facilities in Karnal and Paonta Sahib), and Kemsyn Lifesciences (branded generics, 300+ SKUs). Aggregate annual capacity exceeds 1 billion general tablets, 200 million capsules, 207 million glass vials, 420 million ampoules, and substantial lyophilized and cephalosporin output; product breadth covers 400+ formulations across acute, chronic, hormonal, and sterile therapeutic segments.

The business model combines three distinct go-to-market motions: enterprise field sales for CDMO contracts under Product-to-Product (P2P) and Loan License multi-year arrangements priced on a quote basis; sales-led institutional tender participation and distributor relationships for the Branded Rx Division; and export-led international distribution supported by 30+ country regulatory approvals. Pricing is not publicly disclosed; CDMO contracts are quote-based and dependent on formulation complexity, regulatory requirements, and volume. A January 2023 strategic growth investment by TA Associates (undisclosed amount) supports the ongoing Rs 50 crore capex program aimed at EU GMP compliance and capacity modernization, executed against a zero-debt balance sheet (per Nitin Lifesciences) and a stated historical sales milestone of Rs 8 billion.

Name

Synokem Pharmaceuticals

Legal name

Synokem Pharmaceuticals Ltd.

Website

https://synokempharma.com

Company type

Private

Founded year

1983

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Synokem Pharmaceuticals is an Indian CDMO and pharma manufacturer founded in 1983, operating three WHO-GMP-certified facilities that produce tablets, capsules, injectables, and hormonal products across 400+ formulations, serving pharmaceutical companies, government healthcare institutions, and export markets across 35+ countries.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Scientific Research and Development Services (5417), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

akta.pro secondary industries

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Small-Molecule Generics (Branded/Unbranded) (HLAIABAA), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Pharmaceutical manufacturing
• Contract development manufacturing
• Generic formulations
• Finished dosage forms
• Active pharmaceutical ingredients

Headquarters

HQ city

Delhi

HQ country

India

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Contract Manufacturing / CDMO Services: High-quality development and manufacturing services to leading pharmaceutical companies, branded pharma firms, and biotechnology companies. Operates with Product-to-Product (P2P) and Loan License business models. Provides end-to-end support from formulation development to commercial manufacturing and packaging.
2. Branded Generics (Ethical Division): Ethical promotion of prescription medicines to medical community throughout India. Premium prescription medications in various therapeutic areas with patient-centered care, affordability, and innovation.
3. Institutional Sales: Supply of quality drugs to large government and semi-governmental departments, public sector hospitals, and state procurement organizations. Registered supplier of Indian Railways. Contributes to Jan Aushadhi program through PMBI supplies.
4. International Business: Export operations serving markets across 6 continents with regulatory approvals from countries including Kenya, Sudan, Philippines, Uganda, Yemen, Nigeria, Nepal, and Sri Lanka.

Pricing tiers

Go-to-market motion4 records

Distribution channels4 records

Marketing channels7 records

Core offering

Synokem Pharmaceuticals is a pharmaceutical CDMO and branded-generics manufacturer offering contract development and manufacturing services alongside its own branded prescription products. It produces tablets, capsules, oral liquids, ointments, hormonal products, and injectables across WHO-GMP certified facilities, serving global pharmaceutical clients and institutional buyers across 35+ countries through four verticals: Contract Manufacturing/CDMO, International Business, Institutional Business, and Branded Rx.

Product overview

Synokem Pharmaceuticals is a CDMO (Contract Development and Manufacturing Organization) and globally recognized pharmaceutical company founded in 1983. The company operates as an integrated pharmaceutical player with four interconnected business verticals: Contract Manufacturing/CDMO Services (offering end-to-end formulation development, analytical testing, manufacturing, and packaging), International Business (exporting WHO-GMP certified formulations to 35+ countries), Institutional Business (supplying government and public sector healthcare organizations including Jan Aushadhi program), and Branded Rx/Ethical Division (ethical promotion of prescription medicines in India). The company manufactures over 400 formulations across multiple dosage forms including tablets, capsules, oral liquids, ointments, hormonal products, and injectables through its three WHO-GMP certified facilities in Haridwar and via subsidiaries Synokem Lifesciences (tablets, capsules, liquids), Nitin Lifesciences (injectables, SVP), and Kemsyn Lifesciences (branded generics with 300+ SKUs).

Differentiator

Problem solved

Functional benefit

Products and services

• Contract Manufacturing and Development (CDMO) Services
• Branded Prescription Pharmaceuticals
• Institutional Pharmaceutical Supply
• International Pharmaceutical Exports

Quantifiable outcome

• Rs 8 Billion in sales achieved
• +3 more outcomes

Named customers9 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators17 records

Recent moves8 records

Expansion highlights7 records

Broad incumbents

• Aurobindo Pharma: Large Indian pharmaceutical manufacturer with significant CDMO operations and injectable manufacturing capabilities. A scaled peer competing in similar generics, injectables, and emerging-market export verticals.
• Divi's Laboratories: Leading Indian CDMO specializing in APIs and intermediates with US FDA and EU GMP certifications. Comparable in providing contract manufacturing services to global pharma, though at significantly larger scale.
• Jubilant Pharmova: Integrated Indian pharmaceutical company with CDMO services, generics, and radiopharmaceuticals. Comparable across CDMO, generics, and injectables manufacturing verticals.

Direct peers

• Syngene International: Biocon Group's integrated CDMO offering drug development and manufacturing services to global pharma. A closely comparable Indian CDMO peer, though with deeper biologics and discovery capabilities.
• Piramal Pharma Solutions: Global CDMO offering integrated development and manufacturing services across sterile injectables, oral solids, and APIs. Directly comparable in CDMO services and injectable manufacturing scope.
• Suven Pharmaceuticals: Indian CDMO focused on niche APIs, intermediates, and contract manufacturing. Comparable mid-sized Indian CDMO peer serving global innovator clients.
• Gland Pharma: India-based injectable-focused CDMO with strong US FDA presence, now majority-owned by Fosun. Direct peer in sterile injectables CDMO with comparable manufacturing capabilities and contract development services.
• Natco Pharma: Indian pharmaceutical company with formulation manufacturing, exports to emerging markets, and government/institutional supply. Comparable across branded generics, international business, and institutional verticals.
• Morepen Laboratories: Indian pharmaceutical manufacturer with APIs, formulations, and contract manufacturing. Comparable mid-sized Indian pharma peer across formulation CDMO and branded generics.

Regional players

• Bharat Parenterals: Indian injectables manufacturer specializing in small-volume parenterals. Direct comparable in sterile injectable CDMO capabilities with overlapping capacity profiles.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/synokem-pharmaceuticals-ltd
• Xx.com/Synokem_P
• Facebookfacebook.com/SynokemPharmaceuticals

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries3 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Synokem Pharmaceuticals